Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression

Pharmacology Biochemistry and Behavior

Volumn 96, Issue 2, 2010, Pages 206-210

  Overstreet, David H ^a   Naimoli, V M ^b   Griebel, Guy ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b SANOFI   (France)

Author keywords

Desipramine; Forced swim test; FSL model of depression; Saredutant; Social interaction test

Indexed keywords

DESIPRAMINE; NEUROKININ 2 RECEPTOR ANTAGONIST; SAREDUTANT; ANTIDEPRESSANT AGENT; BENZAMIDE DERIVATIVE; NEUROKININ 2 RECEPTOR; PIPERIDINE DERIVATIVE;

ADD ON THERAPY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FORCED SWIMMING TEST; GENETIC MODEL; IMMOBILIZATION; LOCOMOTION; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SOCIAL INTERACTION; STRAIN DIFFERENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG COMBINATION; INBRED RAT STRAIN; SOCIAL BEHAVIOR; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZAMIDES; DEPRESSION; DESIPRAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; PIPERIDINES; RATS; RATS, INBRED STRAINS; RECEPTORS, NEUROKININ-2; SOCIAL BEHAVIOR; SWIMMING;

ANIMALIA; RATTUS; RODENTIA;

EID: 77953693517     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.05.006     Document Type: Article

References (37)

1. Benca R.M., Overstreet D.H., Gilliland M.A., Russell D., Bergmann B.M., Obermeyer W.H. Increased basal REM sleep but no difference in dark induction or light suppression of REM sleep in Flinders rats with cholinergic supersensitivity. Neuropsychopharmacology 1996, 15:45-51.
2. Bourin M., Chenu F., Prica C., Hascoet M. Augmentation effect of combination therapy of aripiprazone and antidepressants on forced swimming test in mice. Psychopharmacology 2009, 206:97-107.
3. Bradford L.D., Tulp M.T., Schipper J. Biochemical effects in rats after acute and long-term treatment with clovoxamine. Arch Internat Pharmacodyn Ther 1987, 287:188-202.
4. Buell G., Schultz M.F., Arkinstall S.I., Maury K., Missotten M., Adami N., Talabot F., Kawashima E. Molecular characterisation, expression and localisation of human neurokinin-3 receptor. FEBS Lett 1992, 299:90-95.
5. Dableh L.J., Yashpal K., Rochford J., Henry J.L. Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur J Pharmacol 2005, 507:99-105.
6. File S.E., Seth P. A review of 25years of the social interaction test. Eur J Pharmacol 2003, 463:35-53.
7. Gerard N.P., Eddy R.L., Shows T.B., Gerard C. The human neurokinin A (substance K) receptor. J Biol Chem 1990, 265:20445-20462.
8. Gerard N.P., Garrawaar L.A., Eddy R.L., Shows T.B., Iijima H., Paquet J.L., Gerard C. Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones. Biochemistry 1991, 30:10640-10646.
9. Griebel G., Perrault G., Soubrie' P. Effects of SR 48968, a selective non-peptide NK2 receptor antagonist, on emotional processes in rodents. Psychopharmacology 2001, 158:241-251.
10. Husum H., Jiminez-Vasquez P.A., Mathe' A.A. Changed concentrations of tachykinins and neuropeptide Y in the brain of a rat model of depression: lithium treatment normalizes tachykinins. Neuropsychopharmacology 2000, 24:183-191.
11. Janowlsky D.S., Overstreet D.H., Nurnberger J.I. Is cholinergic sensitivity a genetic marker for the affective disorders?. Amer J Med Neuropsychiatric Genetics 1994, 54:335-344.
12. Louis C., Stemmelin J., Boulay D., Bergis O., Cohen C., Griebel G. Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor, in various rodent models. Pharmacol Biochem Behav 2008, 89:36-45.
13. Markou A., Matthews K., Overstreet D.H., Koob M.A., Geer M.A. Flinders resistant hypocholinergic rats exhibit startle sensitization and reduced startle thresholds. Biol Psychiatry 1994, 36:680-688.
14. Mason S.T., Angel A. Behavioural evidence that chronic treatment with the antidepressant desipramine causes reduced functioning of brain noradrenaline systems. Psychopharmacology 1983, 81:73-77.
15. Micale V., Tamburella A., Leggio C., Li Voisi V., Drago F. Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions. Pharmacol Biochem Behav 2008, 90:643-649.
16. Nelson J.C., Mankoski R., Baker R.A., Carlson B.X., Eudicone J.M., Pikolov A., Tran Q.V., Berman R.M. Effects of aripiprazone to standard antidepressant treatment ion the core symptoms of depression; a post-hoc, pooled analysis of two large, placebo-controlled studies. J Affect Disord 2010, 120:133-140.
17. Overstreet D.H. Selective breeding for increased cholinergic function: development of a new animal model of depression. Biol Psychiatry 1986, 21:49-58.
18. Overstreet D.H. The Flinders Sensitive Line rats: a genetic animal model of depression. Neurosci Biobehav Rev 1993, 17:51-68.
19. Overstreet D.H. Behavioral characteristics of rat lines selected for differential hypothermic responses to cholinergic or serotonergic agonists. Behav Genet 2002, 32:335-348.
20. Overstreet D.H., Griebel G. Antidepressant-like effects of CRF1 receptor antagonist SSR125543 in an animal model of depression. Eur J Pharmacol 2004, 497:49-53.
21. Overstreet D.H., Griebel G. Antidepressant-like effects of the vasopressin V1b recetor antagonist SSR149415 in the Flinders Sensitive Line rat. Pharmacol Biochem Behav 2005, 82:223-227.
22. Overstreet D.H., Pucilowski O., Rezvani A.H., Janowsky D.S. Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of the Flinders Sensitive Line rats as an animal model of depression. Psychopharmacology 1995, 121:27-37.
23. Overstreet D.H., Daws L.C., Schiller G.D., Orbach J., Janowsky D.S. Cholinergic/serotonergic interactions in hypothermia; implications for rat models of depression. Pharmacol Biochem Behav 1998, 59:777-785.
24. Overstreet D.H., Knapp D.J., Breese G.R. Accentuated decreases in social interaction in rats subjected to repeated ethanol withdrawals. Alcohol Clin Exp Res 2002, 26:1239-1269.
25. Overstreet D.H., Keeney A.D., Hogg S. Antidepressant effects of citalopram and CRF receptor antagonist CP-154, 526 in a rat model of depression. Eur J Pharmacol 2004, 492:195-201.
26. Overstreet D.H., Hlavka J., Feighner J.P., Nikolau G., Freed J.S. Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression. Psychopharmacology 2004, 175:303-309.
27. Overstreet D.H., Friedman E.F., Mathe A.A., Yadid G. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci Biobehav Rev 2005, 29:739-759.
28. Overstreet D.H., Stemmelin J., Griebel G. Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacol Biochem Behav 2008, 89:63-66.
29. Pucilowski O., Overstreet D.H. Effect of chronic antidepressant treatment on responses to apomorphine in selectively bred rat strains. Pharmacol Biochem Behav 1993, 32:471-475.
30. Regoli D., Boudon A., Fauchere J.L. Receptors and antagonists for substance P and related peptides. Pharmacol Rev 1994, 46:551-599.
31. Salome' N., Stemmelin J., Cohen C., Griebel G. Selective blockade of NK2 or NK3 receptors produces anxiolytic- and antidepressant-like effects in gerbils. Pharmacol Biochem Behav 2006, 83:533-539.
32. Schiller G.D., Daws L.C., Overstreet D.H., Orbach J. Absence of anxiety in an animal model of depression with cholinergic supersensitivity. Brain Res Bull 1991, 26:443-447.
33. Severini C., Improta G., Falconieri-Erspamer G., Salvadori S., Erspamer V. The tachykinin peptide family. Pharmacol Rev 2002, 285-322.
34. Shiromani P.J., Overstreet D.H., Levy D., Goodrich G.A., Campbell S.S., Gillin J.C. Increased REM sleep in rats selectively bred for cholineric hyperactivity. Neuropsychopharmacoology 1988, 1:127-133.
35. Steinberg R., Alonso R., Griebel G., Bert O.L., Jung M., Oury-Donat F., Poncelet M., Gueudet C., Desvignes C., Le Fur G., Soubrie' P. Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function. J Pharmacol Exp Ther 2001, 299:449-458.
36. Zangen A., Overstreet D.H., Yadid G. High serotonin and 5-hydroxyindoleacetic acid levels in limbic brain regions in a rat model of depression: normalization by chronic antidepressant treatment. J Neurochem 1997, 69:2477-2483.
37. Zangen A., Overstreet D.H., Yadid G. Increased catecholamine levels in specific brain regions of a rat model of depression: normalization by chronic antidepressant treatment. Brain Res 1999, 824:243-250.